BioAge Labs宣布BGE-102概念验证二期试验Quell-Cv完成首例患者给药,该口服NLRP3抑制剂针对心血管风险升高人群

美股速递
Jun 16

BioAge Labs公司宣布,其新型口服NLRP3抑制剂BGE-102的概念验证二期临床试验Quell-Cv,已成功为第一位参与者完成给药。该试验主要面向心血管风险升高的患者群体。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10